RT @Gibson_RheumPAC GLP-1 receptor agonists do more than promote weight loss. They impact insulin resistance, inflammation, cardiovascular risk—and may influence musculoskeletal disease. #RNL26 https://t.co/ypKnOJojAm

We are Doctors, Not Providers! With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians (ACP) is concerned about the use of the term provider to describe physicians. https://t.co/Vf6Wx0w28d https://t.co/RXTTFq34Rj

Staying Ahead of Spondyloarthritis The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis." https://t.co/hZeqYC7wi3 https://t.co/2eKEueAukY

RT @richardPAconway Dr Sparks shows risk factors for RA-ILD. Important for diagnosis (and screening?) Focus interventions on the modifiable ones! #RNL26 https://t.co/lE9Mkbq8oh

RT @richardPAconway UIP is predominant radiologic pattern in RA-ILD. Contrast with our other diseases. But by no means exclusive - up to 50% of RA-ILD have a more inflammatory pattern. Important treatment implications! #RNL26 https://t.co/HmW1mz429i

RT @richardPAconway Updated data on RA-ILD from Olmstead County. Cumulative incidence of 15.3% over 20 years! #RNL26 https://t.co/wVrTc3QM6Y

Dr. Fleischman on lupus dz activity including SLEDAI, which you can use on practice. But not for practice are SLE-DAS, BILAG, BICLA, SRI-4, DORIS @RWCSmtg #RWCS26 https://t.co/7sOaE7SMht

Advances in RA-ILD Dr. Jeffrey Sparks gave a state of the art update on Advances in RA-ILD, many of which he and his group have played a big part in, on Saturday at RNL26. https://t.co/xO7hBRKeqE https://t.co/rs1MS08Svl

RT @ericdeinmd Mucosal Hypothesis RA #RNL26 Demoruelle ACPA can predate RA development Nam et al: non-specific jt pain: 42% developed RA in 12 mos Circiumaro et al: MSK complaints 38% devel RA in 36 mo APIPPRA: 29% at 12 mo, 37% at 24 mo, StopRA 18% in 12 mo, 33% at 36 mo https://t.co/DxGhhFL1gO

RT @Gibson_RheumPAC Nearly 50% of U.S. adults may meet criteria for obesity by 2030. For rheumatologists, it directly impacts disease activity, outcomes, and treatment response. #RNL26 https://t.co/cpy4LBBPHc

RT @gibson_RheumPAC Osteoarthritis affects 600 million people worldwide—yet we still have no approved disease-modifying therapies. A powerful opening to this talk on why OA drug development keeps missing the mark. https://t.co/wBUN3lux6X